Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
about
EGFR C797S mutation mediates resistance to third-generation inhibitors in T790M-positive non-small cell lung cancerTargeting B-cell receptor signaling kinases in chronic lymphocytic leukemia: the promise of entospletinibRole of the tumor microenvironment in mature B-cell lymphoid malignanciesIbrutinib: Implications for Use in the Treatment of Mantle Cell Lymphoma and Chronic Lymphocytic LeukemiaCD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasChronic lymphocytic leukemia: a clinical review including Korean cohortsChronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted AgentsBCR Signaling Inhibitors: an Overview of Toxicities Associated with Ibrutinib and Idelalisib in Patients with Chronic Lymphocytic LeukemiaCurrent concepts in diagnosis and treatment of chronic lymphocytic leukemiaTCL1 transgenic mouse model as a tool for the study of therapeutic targets and microenvironment in human B-cell chronic lymphocytic leukemiaIbrutinibThe role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemiaManagement of Chronic Lymphocytic Leukemia in the ElderlyPI3K and AKT: Unfaithful Partners in CancerKnow the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemiaNovel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma TherapyPI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)Lymphoma Immunotherapy: Current StatusIbrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinionCancer stem cells are the cause of drug resistance in multiple myeloma: fact or fiction?Role of Tyrosine Kinase Inhibitors in Indolent and Other Mature B-Cell NeoplasmsObinutuzumab for the treatment of patients with previously untreated chronic lymphocytic leukemia: overview and perspectiveMyeloid Cells as Targets for Therapy in Solid TumorsPredictive biomarkers in precision medicine and drug development against lung cancerNew strategies in chronic lymphocytic leukemia: shifting treatment paradigmsTen things you should know about protein kinases: IUPHAR Review 14Risk of Infectious Complications in Hemato-Oncological Patients Treated with Kinase InhibitorsThe outcome of B-cell receptor signaling in chronic lymphocytic leukemia: proliferation or anergyBruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomasBruton's tyrosine kinase inhibitors and their clinical potential in the treatment of B-cell malignancies: focus on ibrutinibTargeted therapies in CLL: mechanisms of resistance and strategies for managementB cell receptor pathway in chronic lymphocytic leukemia: specific role of CC-292High-dimensional single-cell cancer biologyHow will B-cell-receptor-targeted therapies change future CLL therapy?Targeting neoplastic B cells and harnessing microenvironment: the "double face" of ibrutinib and idelalisibIbrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinaseNovel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive reviewAACR Cancer Progress Report 2014The tumor microenvironment shapes hallmarks of mature B-cell malignancies.Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib
P2860
Q26741998-A1C17336-0A60-413F-AB65-C23C212BDAE5Q26744277-84EECFC9-B189-44BD-8B22-C43C46C18B55Q26748775-FE5A11EC-6945-4A7E-BE2A-8B969BB56C20Q26749010-B551A25A-DE7C-4A5F-B206-D0290418176BQ26749139-1FD47461-6C71-4693-8947-153D124FC94FQ26752467-6D72CFE2-E62E-4E4B-9C33-904CC29964B6Q26764833-198FE934-9E4F-44C2-A201-BB909FBFECDBQ26765624-4F23BA6D-2243-4B3C-A0F5-990D3F2B9D4FQ26770471-5CB02ADF-DCCC-426F-B2D8-0D3CFFCBBB5DQ26773053-DF670DD5-848C-4AE6-AC41-621E00975A71Q26773236-D6C8D241-DF39-4401-B416-EE52B72426F8Q26775506-1790594D-8056-4A10-83B1-9DD1A1FB0D36Q26775983-F0888549-191B-448F-891E-C3C0975D96C8Q26781367-70302C56-3EE7-434C-A1CB-85E160F54258Q26781895-F16E3E51-023C-40CB-9F5F-F6B1251736EBQ26782270-12478A50-7CA8-4919-A93C-BAB507D8E3E1Q26782633-BBC6B65C-A86F-4C65-BE28-43691AB8FB32Q26782902-914C636C-22AB-41F0-9889-2CF8346A44A2Q26783430-DE558931-FF83-4BB5-B38C-51BC9712D6DCQ26785497-0BF62014-5A85-46A7-82BA-735615296246Q26795594-1875EBED-8A89-4947-9677-EF7A25569003Q26796455-9B4D21B1-779D-45E8-ACF7-C2DFCFFAD4B2Q26801832-6568D4C2-57AD-403A-BFB1-3E784C2BFE98Q26824536-5835BC37-DB0C-4AD8-89EE-5E50B865A931Q26828496-699864C1-EAB9-48A5-ADC0-6363E0DA0553Q26849417-0BD1A9B2-8DAC-462C-82DE-690EBADBDB9FQ26851417-77377B5F-174F-46DF-95E1-C27B3866F56FQ26865760-31827CC6-9080-4E9F-8E91-B616F3FDB10EQ26991890-5210A561-9C7E-410A-A446-90B39E122B6EQ26995113-819CBFA6-8A79-45FB-A441-8B09B565A34DQ27002528-0A398AC6-DA88-45A2-85FA-C2407C314236Q27009550-F7F3D09F-22C9-49A2-B76C-1D2222150849Q27021173-97D56FC6-2A57-42B7-AE59-299BD75994E9Q27024187-FB7FEE82-7E74-47FC-91A1-3B0A82BB1133Q27025812-D65844A9-08B9-45E3-9327-0E9E1BC6E381Q27026912-A1FCB9B5-EBD4-4991-87E2-C15F57DBAC78Q27304386-5DC9DCD7-CE9A-4E02-9A40-BA49D6150207Q27346723-7CCFC29E-63B5-4335-8A10-4EC851E85C49Q27687567-7D645514-2341-427C-82C7-7F04C9F6C58CQ27853011-E6AC104E-0228-4852-B2DD-6FBB18A9C958
P2860
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
@ast
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
@en
type
label
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
@ast
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
@en
prefLabel
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
@ast
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
@en
P2093
P2860
P921
P3181
P356
P1476
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
@en
P2093
Amy J Johnson
Barbara Grant
Betty Y Chang
Danelle F James
Eric Hedrick
Jan A Burger
Jeff P Sharman
Jeffrey A Jones
John C Byrd
P2860
P356
10.1056/NEJMOA1215637
P407
P577
2013-06-19T00:00:00Z